- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00963105
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
A Phase 2, Multi-Center, Randomized, Double-Blinded, Parallel Group Study of the Safety and Efficacy of Different Lenalidomide (REVLIMID®) Dose Regimens in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Barcelona, Espanja, 08916
- Hospital Universitari Germans Trias i Pujol
-
Barcelona, Espanja, 08036
- Hospital Clinic provincial de Barcelona
-
-
-
-
-
Genova, Italia, 16132
- Azienda Ospedaliera Universitaria San Martino
-
Lecce, Italia, 73100
- Ematologia ed Immunologia, Azienda Ospedaliera "Vito Fazzi" di Lecce
-
Milano, Italia, 20141
- Istituto Europeo Di Oncologia - IEO
-
Milano, Italia, 20132
- I.R.C.C.S. Ospedale San Raffaele
-
Padova, Italia, 35128
- Universita degli Studi di Padova
-
Perugia, Italia, 06100
- Universita' degli Studi di Perugia
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 1Z2
- Cross Cancer Institute
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8V 5C2
- Juravinski Cancer Centre
-
-
-
-
-
Amiens, Ranska, 80054
- CHU Sud
-
Bobigny Cedex, Ranska, 93009
- Hôpital Avicenne
-
Grenoble Cedex 09, Ranska, 38043
- CHU Grenoble
-
Le Mans, Ranska, 72000
- Clinique Victor Hugo
-
Marseille Cedex 9, Ranska, 13273
- Institut Paoli Calmettes
-
Montpellier Cedex 5, Ranska, 34295
- CHU Montpellier - Hôpital Saint Eloi
-
Mulhouse, Ranska, 68000
- Hôpital Emile Muller
-
Paris, Ranska, 75651
- Hôpital Pitié Salpêtrière
-
Perpignan, Ranska, 66046
- CH Perpignan - Hopital Saint-Jean
-
Pessac, Ranska, 33604
- CHRU - Hôpital du Haut Lévêque
-
Pierre Bénite, Ranska, 69310
- Centre Hospitalier Lyon Sud
-
REIMS cedex, Ranska, 51092
- Hôpital Robert Debré
-
Rennes cedex, Ranska, 35033
- CHU Rennes Hematology
-
Vandoeuvre les Nancy, Ranska, 54511
- CHRU Hopital Brabois
-
-
-
-
-
Stockholm, Ruotsi, 14186
- Karolinska Universitetssjukhuset
-
-
-
-
-
Berlin, Saksa, 13353
- Charité -Universitätsmedizin Berlin
-
Essen, Saksa, 45122
- Universitätsklinikum Essen
-
Greifswald, Saksa, 17487
- Ernst-Moritz-Arndt-Universität Greifswald
-
Kiel, Saksa, 24116
- Universitatsklinikum Schleswig Holstein
-
Köln, Saksa, 50924
- Klinikum der Universität zu Köln
-
Ulm, Saksa, 89081
- University of Ulm Abteilung Innere Medizin III
-
-
-
-
-
Leeds, Yhdistynyt kuningaskunta, LS9 7TF
- St James's Institute of Oncology
-
London, Yhdistynyt kuningaskunta, SE5 9RS
- King's College Hospital
-
London, Yhdistynyt kuningaskunta, SW3 6JJ
- The Royal Marsden Hospital
-
London, Yhdistynyt kuningaskunta, EC1M 6BQ
- St.Bartholomew's Hospital
-
Manchester, Yhdistynyt kuningaskunta, M20 4BX
- Christie Hospital NHS Foundation Trust
-
-
-
-
California
-
La Jolla, California, Yhdysvallat, 92093-0820
- UCSD Moores Cancer Center
-
Rancho Mirage, California, Yhdysvallat, 92270
- Desert Hematology Oncology Medical Group, Inc.
-
Stanford, California, Yhdysvallat, 94305-5821
- Stanford University School of Medicine
-
-
Connecticut
-
Southington, Connecticut, Yhdysvallat, 06489
- Cancer Center of Central Connecticut
-
-
Florida
-
Lecanto, Florida, Yhdysvallat, 34461
- Cancer and Blood Disease Center
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60612
- Rush University Medical Center
-
Chicago, Illinois, Yhdysvallat, 60611-2927
- Northwestern University Medical Center Division of Hematology Oncology
-
-
Indiana
-
Indianapolis, Indiana, Yhdysvallat, 46202-5149
- Indiana University Cancer Center
-
-
Michigan
-
Detroit, Michigan, Yhdysvallat, 48201
- Karmanos Cancer Institute
-
-
New Jersey
-
Hackensack, New Jersey, Yhdysvallat, 07601
- Hackensack University Medical Center
-
-
New York
-
Buffalo, New York, Yhdysvallat, 14263
- Roswell Park Cancer Institute
-
New Hyde Park, New York, Yhdysvallat, 11042
- Long Island Jewish Medical Center CLL Research and Treatment Program
-
-
North Carolina
-
Winston-Salem, North Carolina, Yhdysvallat, 27104
- Wake Forest University School of Medicine
-
-
Ohio
-
Canton, Ohio, Yhdysvallat, 44718
- Gabrail Cancer Center Research
-
Cleveland, Ohio, Yhdysvallat, 44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19102
- Drexel University, College of Medicine, Clinical Research Group
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age ≥ 18 years at the time of signing the informed consent form
- Must be able to adhere to the study visit schedule and other protocol requirements
- Must have a documented diagnosis of B-cell CLL
- Must be relapsed or refractory to at least 1 regimen for treatment of CLL. At least one of the prior treatments must have included a purine analog-based or bendamustine-based regimen
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2.
Exclusion Criteria:
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
- Active infections requiring systemic antibiotics
- Systemic treatment for B-cell CLL within 28 days of initiation of lenalidomide treatment
- Alemtuzumab therapy within 120 days of initiating lenalidomide treatment
- Prior therapy with lenalidomide
- History of grade 4 rash due to prior thalidomide treatment
- Planned autologous or allogeneic bone marrow transplantation
- Central nervous system (CNS) involvement as documented by spinal fluid cytology or imaging.
- Uncontrolled hyperthyroidism or hypothyroidism
- Venous thromboembolism within 12 months
- ≥ Grade 2 neuropathy
- Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
- Disease transformation [i.e. Richter's Syndrome (lymphomas) or prolymphocytic leukemia]
- Participation in any clinical study or having taken any investigational therapy within 28 days prior to initiating lenalidomide therapy
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Lenalidomide 5 mg
Participants received a starting dose of 5 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability. Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug |
Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:
|
Kokeellinen: Lenalidomide 10 mg
Participants received a starting dose of 10 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability. Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug |
Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:
|
Kokeellinen: Lenalidomide 15 mg
Participants received a starting dose of 15 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability. Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug |
Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Number of Participants With Treatment-emergent Adverse Events
Aikaikkuna: From first dose of study drug to 30 days after the last dose; the maximum duration of treatment was 251, 265, and 267 weeks in the 5 mg, 10 mg, and 15 mg treatment groups respectively.
|
Adverse events (AEs) were graded for severity by the investigator according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 with the exceptions of hematologic toxicities and tumor lysis syndrome, according to the following scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening or disabling AE Grade 5 = Death The investigator determined the relationship of each AE to study drug based on the timing of the AE and whether other medications, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the observed event.
|
From first dose of study drug to 30 days after the last dose; the maximum duration of treatment was 251, 265, and 267 weeks in the 5 mg, 10 mg, and 15 mg treatment groups respectively.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Overall Response Rate (ORR)
Aikaikkuna: Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
|
ORR was defined as the percentage of patients with a complete response (CR), CR with incomplete bone marrow (BM) recovery (CRi) or partial response (PR) during treatment.
Response was assessed according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines.
Per the guidelines, a CR required peripheral blood lymphocytes below 4 x 10^9/L, absence of lymphadenopathy, no hepatomegaly or splenomegaly, absence of disease and blood counts neutrophils >1.5 x 10^9/L, platelets >100 x 10^9/L, hemoglobin (hgb) >11g/dL) and BM at least normocellular for age.
CRi = CR with incomplete BM recovery.
PR = required at least 2 months from end of treatment, a ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value and either a ≥ 50% reduction in lymphadenopathy or ≥50% reduction of liver enlargement or ≥50% reduction of spleen enlargement plus neutrophils >1.5 x 10^9/ or ≥50% increase, platelets >100 x 10^9/L or ≥50% increase, hgb 11 g/dL.
|
Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
|
Kaplan-Meier Estimate of Duration of Response
Aikaikkuna: Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
|
Duration of response (DOR) was defined as the time from the first visit where PR, CRi, or CR was documented to progressive disease (PD).
Duration of response was censored at the last date that the participant was known to be progression-free for participants who had not progressed at the time of analysis or who withdrew consent or were lost to follow-up prior to documentation of progression.
|
Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
|
Time to Response
Aikaikkuna: Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
|
Time to response (TTR) was calculated as the time from randomization to the first documented date of response (PR, CRi or CR) based on iwCLL guidelines for participants with an objective response during the treatment period.
|
Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
|
Kaplan-Meier Estimate of Time to Progression
Aikaikkuna: From randomization until the end of the study; maximum time on study was 91 months.
|
Time to progression (TTP) was defined as the time from randomization to the first documented progression.
For participants who did not progress during the study, TTP was censored at the last adequate response assessment showing evidence of no disease progression.
|
From randomization until the end of the study; maximum time on study was 91 months.
|
Kaplan-Meier Estimate of Event-Free Survival
Aikaikkuna: From randomization until the end of the study; maximum time on study was 91 months.
|
Event-free survival (EFS) is the interval between the start of treatment to the first sign of disease progression, or treatment for relapse or death (whichever occurred first).
If withdrawal of consent or loss to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.
|
From randomization until the end of the study; maximum time on study was 91 months.
|
Kaplan-Meier Estimate of Progression Free Survival
Aikaikkuna: From randomization until the end of the study; maximum time on study was 91 months.
|
Progression-free survival (PFS) was calculated as the time from randomization to the first documented progression or death due to any cause during or after the treatment period, whichever occurred first.
The progression date was assigned to the earliest time when any progression is observed without prior missing assessments.
If withdrawal of consent or loss to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.
|
From randomization until the end of the study; maximum time on study was 91 months.
|
Kaplan-Meier Estimate of Overall Survival
Aikaikkuna: From randomization until the end of the study; maximum time on study was 91 months.
|
Overall survival (OS) was defined as the time from randomization to death from any cause.
Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who had withdrawn consent or were lost to follow-up before death was documented.
|
From randomization until the end of the study; maximum time on study was 91 months.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Jeffery Jones, M.D., MPH, Celgene Corporation
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Durig J, Kalaycio M, Gribben JG, Stilgenbauer S, Buhler A, Kipps TJ, Purse B, Zhang J, De Bedout S, Mei J, Chanan-Khan A. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016;57(6):1291-9. doi: 10.3109/10428194.2015.1128540. Epub 2016 Jan 14.
- Buhler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Durig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J. 2016 Mar 11;6(3):e404. doi: 10.1038/bcj.2016.9.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Immuunijärjestelmän sairaudet
- Neoplasmat histologisen tyypin mukaan
- Neoplasmat
- Lymfoproliferatiiviset häiriöt
- Lymfaattiset sairaudet
- Immunoproliferatiiviset häiriöt
- Leukemia, B-solu
- Leukemia
- Leukemia, lymfosyyttinen, krooninen, B-solu
- Leukemia, imusolmukkeet
- Huumeiden fysiologiset vaikutukset
- Antineoplastiset aineet
- Immunologiset tekijät
- Angiogeneesin estäjät
- Angiogeneesiä moduloivat aineet
- Kasvuaineet
- Kasvun estäjät
- Lenalidomidi
Muut tutkimustunnusnumerot
- CC-5013-CLL-009
- 2009-009836-54 (EudraCT-numero)
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset lenalidomide
-
University Hopsital Schleswig Holstein Campus LübeckRekrytointiÄskettäin diagnosoitu multippeli myeloomaSaksa